The tracer, F-18 APN-1607, can recognize tau proteins in pathological aggregated states but not normal physiological ones. It is part of a new generation of tau radiotracers that have better selectivity and off-target binding profiles, the company noted.
The phase III trial is the next step toward commercialization of the radiotracer. It will evaluate the safety and efficacy of F-18 APN-1607 to differentiate patients with cognitive impairment from healthy subjects. The trial intends to enroll about 230 subjects, including patients with mild cognitive impairment and various stages of Alzheimer's disease.
Copyright © 2020 AuntMinnie.com